|
New Software Maximizes Data Consistency for BD Flow Cytometers Performing Cell Research
Contact: Jeff Ezell BD Public Relations (201) 847-5533 Email: jeff_ezell@bd.com San Jose, CA (June 29, 2007) -- BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of BD FACSDiva™ 6.0 software. This automated package will help scientists attain the best performance and most consistent data from BD flow cytometry systems used for important basic and clinical research. “BD’s advanced flow cytometry systems are the foundation for key medical research that requires the measurement and charting of cell characteristics and properties,” said Bill Rhodes, President, Cell Analysis, BD Biosciences. “BD FACSDiva software is the most complete flow cytometer standardization system ever devised. Researchers and clinicians are no longer limited in the design and performance of high-level, multi-color experiments by the complexity of their flow cytometer setup. This new software, with our new BD™ Cytometer Setup and Tracking beads, delivers efficiencies, ease of use, and consistent, reproducible results with decreased downtime — all of which are essential to modern research and clinical laboratories.” BD FACSDiva 6.0 software includes BD™ Cytometer Setup and Tracking capability. This set of features characterizes and automates setup of the BD FACSCanto™, new BD FACSCanto™ II, BD™ LSR II, and BD FACSAria™ flow cytometry systems. Its benefits include:
About BD BD, a leading global medical technology company that manufactures and sells medical devices, instruments and reagents, is dedicated to improving people’s health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 27,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit, www.bd.com. ***
|